Get the Stockscreener App
1.07
0.00%
0.00
Lexicon Pharmaceuticals Inc stock is traded at $1.07, with a volume of 1.13M.
It is up +0.00% in the last 24 hours and up +21.03% over the past month.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
See More
Previous Close:
$1.07
Open:
$1.07
24h Volume:
1.13M
Relative Volume:
0.27
Market Cap:
$388.60M
Revenue:
$1.21M
Net Income/Loss:
$-177.12M
P/E Ratio:
-1.3375
EPS:
-0.8
Net Cash Flow:
$-162.37M
1W Performance:
-2.73%
1M Performance:
+21.03%
6M Performance:
+41.50%
1Y Performance:
-47.03%
1-Day Range:
$1.0401
$1.10
1-Week Range:
$1.00
$1.13
52-Week Range:
$0.2836
$2.175
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Name
Lexicon Pharmaceuticals Inc
Sector
Industry
Phone
(281) 863-3000
Address
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Compare LXRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.07 | 388.60M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-17-24 | Initiated | H.C. Wainwright | Buy |
| Apr-30-24 | Initiated | Leerink Partners | Outperform |
| Mar-07-23 | Initiated | Jefferies | Hold |
| Aug-12-22 | Initiated | Piper Sandler | Overweight |
| Jan-29-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-29-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-18-20 | Upgrade | Gabelli & Co | Hold → Buy |
| Dec-11-19 | Downgrade | Gabelli & Co | Buy → Hold |
| Nov-08-19 | Downgrade | Citigroup | Buy → Neutral |
| Sep-11-19 | Upgrade | Gabelli & Co | Hold → Buy |
| Jul-29-19 | Downgrade | Stifel | Buy → Hold |
| Mar-25-19 | Upgrade | Gabelli & Co | Sell → Hold |
| Jul-31-18 | Reiterated | Stifel | Buy |
| Feb-23-18 | Downgrade | Needham | Buy → Hold |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-01-17 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-17 | Reiterated | Wedbush | Outperform |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Aug-05-16 | Reiterated | Wedbush | Outperform |
| Aug-02-16 | Initiated | Citigroup | Buy |
| Mar-02-16 | Reiterated | Wedbush | Outperform |
| Nov-09-15 | Reiterated | Wedbush | Outperform |
| Sep-28-15 | Upgrade | Gabelli & Co | Sell → Hold |
| Sep-18-15 | Downgrade | Gabelli & Co | Hold → Sell |
| Aug-10-15 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Lexicon Pharmaceuticals Inc Stock (LXRX) Latest News
H.C. Wainwright Reiterates a Buy Rating on Lexicon Pharmaceuticals (LXRX) - MSN
How does Lexicon Pharmaceuticals Inc. compare to its industry peersPre Market Forecasts For Smart Trading - jammulinksnews.com
Why Lexicon Pharmaceuticals Inc. stock attracts strong analyst attentionLow Risk Swing Trade Opportunities Identified - metal.it
Lexicon Pharmaceuticals regains Nasdaq compliance - Investing.com Australia
Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement - The Manila Times
Is Lexicon Pharmaceuticals Inc. stock overvalued or undervaluedStock Strategy Data Feed With High Returns - jammulinksnews.com
How sentiment analysis helps forecast Lexicon Pharmaceuticals Inc.Capital Protection Trading Strategies Gain Interest - metal.it
Technical Charts Suggest Momentum Shift in Lexicon Pharmaceuticals Inc.High Return Stock Focus With Safety Emphasized - metal.it
Why is Lexicon Pharmaceuticals Inc. stock attracting strong analyst attentionExpert Picks Guidance For 2025 - jammulinksnews.com
Is Lexicon Pharmaceuticals Inc. a growth stock or a value stockTrack top-performing stocks effortlessly - jammulinksnews.com
Should I hold or sell Lexicon Pharmaceuticals Inc. stock in 2025Lightning-fast capital gains - jammulinksnews.com
How strong is Lexicon Pharmaceuticals Inc. company’s balance sheetDynamic investment growth - jammulinksnews.com
What makes Lexicon Pharmaceuticals Inc. stock price move sharplyStay informed with expert market forecasts - jammulinksnews.com
How volatile is Lexicon Pharmaceuticals Inc. stock compared to the marketMaximize portfolio growth with strategic plans - jammulinksnews.com
Lexicon Pharmaceuticals regains Nasdaq compliance for minimum bid price - Investing.com
Lexicon Pharmaceuticals regains Nasdaq compliance for minimum bid price By Investing.com - Investing.com India
What is Lexicon Pharmaceuticals Inc. company’s growth strategyGet expert advice on portfolio optimization - jammulinksnews.com
There's Reason For Concern Over Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Massive 34% Price Jump - simplywall.st
New Product Launches: Will They Boost Lexicon Pharmaceuticals Inc. Stock in 2025 - metal.it
What is the dividend policy of Lexicon Pharmaceuticals Inc. stockMarket-leading growth rates - jammulinksnews.com
Painful Week for Private Equity Firms Invested in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After 16% Drop, Institutions Also Suffered Losses - 富途牛牛
Is Lexicon Pharmaceuticals Inc. a good long term investmentFree Investment Case Studies - PrintWeekIndia
Lexicon Pharmaceuticals Inc. Stock Analysis and ForecastExceptional profit velocity - PrintWeekIndia
What drives Lexicon Pharmaceuticals Inc. stock priceFree Smart Trading Workshop - Autocar Professional
What analysts say about Lexicon Pharmaceuticals Inc. stockRobust investment performance - jammulinksnews.com
Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025 - The Manila Times
Lexicon Pharmaceuticals Scheduled to Release Q2 2025 Financial Results and Conduct Conference Call on August 6, 2025 - Nasdaq
Lexicon Pharmaceuticals Schedules Pre-Market Q2 Earnings Release, 8:30 AM ET Conference Call - Stock Titan
Lexicon Pharmaceuticals: A High-Potential Biotech Play in the Diabetes Space - AInvest
Lexicon Pharmaceuticals Inc Stock (LXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lexicon Pharmaceuticals Inc Stock (LXRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sullivan Diane E. | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
36,810 |
| SOBECKI CHRISTOPHER J | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
203,865 |
| BARKER SAM L | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
124,459 |
| Amouyal Philippe | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
285,174 |
| DEBBANE RAYMOND | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
1,385,689 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):